Loomis Sayles & Co. L P Has $97.19 Million Holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Loomis Sayles & Co. L P decreased its holdings in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 2.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,207,060 shares of the company’s stock after selling 36,207 shares during the quarter. Loomis Sayles & Co. L P’s holdings in PROCEPT BioRobotics were worth $97,192,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in PRCT. Raleigh Capital Management Inc. bought a new position in shares of PROCEPT BioRobotics during the 4th quarter worth approximately $32,000. Signaturefd LLC grew its holdings in shares of PROCEPT BioRobotics by 26.7% in the 4th quarter. Signaturefd LLC now owns 689 shares of the company’s stock valued at $55,000 after acquiring an additional 145 shares in the last quarter. IFP Advisors Inc acquired a new position in shares of PROCEPT BioRobotics during the 4th quarter worth about $58,000. Arcadia Investment Management Corp MI acquired a new stake in shares of PROCEPT BioRobotics in the fourth quarter valued at approximately $64,000. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of PROCEPT BioRobotics in the third quarter valued at $64,000. Institutional investors own 89.46% of the company’s stock.

Insider Buying and Selling at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CEO Reza Zadno sold 5,475 shares of PROCEPT BioRobotics stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $312,403.50. Following the completion of the sale, the chief executive officer now owns 173,070 shares of the company’s stock, valued at approximately $9,875,374.20. This trade represents a 3.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Kevin Waters sold 733 shares of the business’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $41,824.98. Following the sale, the chief financial officer now owns 107,991 shares of the company’s stock, valued at approximately $6,161,966.46. This represents a 0.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 6,455 shares of company stock valued at $368,322. 17.40% of the stock is currently owned by company insiders.

PROCEPT BioRobotics Price Performance

PROCEPT BioRobotics stock opened at $62.33 on Thursday. The stock has a market cap of $3.42 billion, a price-to-earnings ratio of -31.96 and a beta of 1.05. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. The business has a 50-day simple moving average of $66.32 and a 200 day simple moving average of $78.15. PROCEPT BioRobotics Co. has a 52 week low of $45.56 and a 52 week high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The business had revenue of $68.24 million for the quarter, compared to analysts’ expectations of $66.79 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. On average, research analysts forecast that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on PRCT. Wells Fargo & Company restated an “overweight” rating and set a $112.00 price objective on shares of PROCEPT BioRobotics in a research note on Tuesday, December 3rd. Truist Financial reissued a “buy” rating and set a $90.00 target price (down previously from $105.00) on shares of PROCEPT BioRobotics in a research note on Wednesday, February 26th. Finally, Morgan Stanley decreased their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating for the company in a research report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $94.29.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).